Highlights Orphazyme A/S

Equities

ORPHA

DK0062502894

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 25/06/2024 pm IST			5-day change	1st Jan Change
922 ^DKK	-6.23%		-5.53%	-30.68%

27/03	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04/03	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
FDA Extends Review of Zevra's Arimoclomol by Three Months	04/03	DJ
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	21/02	CI
Zevra Therapeutics Refiles Arimoclomol Application With FDA	27/12	DJ
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	12/23/12	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	12/23/12	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	30/23/30	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	26/23/26	CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2022	26/23/26	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Orphazyme A/S Revises Earnings Guidance for the Year 2022	26/22/26	CI
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2021	08/22/08	CI
Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022	08/22/08	CI
Orphazyme Closes $18 Million Sale Of Assets, Business Operations Under Restructuring Plan	01/22/01	MT
KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.	31/22/31	CI
KemPharm Agrees to Buy Orphazyme for $12.8 Million	16/22/16	MT
KemPharm Denmark A/S agreed to acquire substantially all assets and business activities of Orphazyme A/S for $18 million.	15/22/15	CI
Orphazyme A/S Announces Withdrawal of European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C	22/22/22	CI
Orphazyme to Halve Workforce to Cut Costs, to Delist from Nasdaq -- Stock Dives 40% After-Hours	11/22/11	MT
Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union	24/22/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Orphazyme A/S

Equities

ORPHA

DK0062502894

Highlights

Filters